Cancer of the uterine cervix

New England Journal of Medicine

Volumn 334, Issue 16, 1996, Pages 1030-1038

  Cannistra, Stephen A ^a,c   Niloff, Jonathan M ^b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN A2; CISPLATIN; VINCRISTINE; VIRUS PROTEIN;

CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; CARCINOMA IN SITU; CELL CYCLE; FEMALE; HIGH RISK POPULATION; HUMAN; MEDICAL ASSESSMENT; PAPANICOLAOU TEST; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; UTERINE CERVIX CANCER; WART VIRUS;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PAPILLOMAVIRIDAE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 0029880366     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199604183341606     Document Type: Review

References (100)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45 8-30. [Erratum, CA Cancer J Clin 1995;45:127-8.]
2. Barber HRK. Incidence, prevalence, and median survival rates of gynecologic cancer. In: Van Nagell JR, Barber HRK, eds. Modern concepts of gynecologic oncology. Boston: John Wright-PSG, 1982 1-19.
3. Cramer DW, Cutler SJ Incidence and histopathology of malignancies of the female genital organs in the United States. Am J Obstet Gynecol 1974; 118.443-60.
4. Richart RM Cervical intraepithelial neoplasia Pathol Annu 1973;8:301-28.
5. Christopherson WM, Parker JE. Relation of cervical cancer to early marriage and childbearing N Engl J Med 1965,273:235-9.
6. Winkelstein W Jr. Smoking and cervical cancer - current status: a review. Am J Epidemiol 1990;131 945-57.
7. Rotkin ID Epidemiology of cancer of the cervix. 3. Sexual characteristics of a cervical cancer population. Am J Public Health Nations Health 1967, 57:815-29.
8. Kessler II. Human cervical cancer as a venereal disease. Cancer Res 1976, 36 783-91.
9. Halpert R, Fruchter RG, Sedlis A, Butt K, Boyce JG, Sillman FH Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 1986;68.251-8
10. Schneider V, Kay S, Lee HM. Immunosuppression as a high-risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytol 1983;27:220-4.
11. Katz RL, Veanattukalathil S, Weiss KM Human papillomavirus infection and neoplasia of the cervix and anogenital region in women with Hodgkin's disease. Acta Cytol 1987,31:845-54.
12. Klein RS, Ho GYF, Vermund SH, Fleming I, Burk RD. Risk factors for squamous intraepithelial lesions on Pap smear in women at risk for human immunodeficiency virus infection J Infect Dis 1994,170 1404-9.
13. Maiman M, Fruchter RG, Guy L, Cuthill S, Levine P, Serur E. Human immunodeficiency virus infection and invasive cervical carcinoma. Cancer 1993,71:402-6
14. Maiman M, Fruchter RG, Serur E, Remy JC, Feuer G, Boyce J. Human immunodeficiency virus infection and cervical neoplasia Gynecol Oncol 1990;38:377-82
15. Meisels A, Fortin R. Condylomatous lesions of the cervix and vagina I. Cytologic patterns. Acta Cytol 1976;20:505-9.
16. Crum CP, Levine RU. Human papillomavirus infection and cervical neoplasia. new perspectives. Int J Gynecol Pathol 1984,3:376-88
17. Lorincz AT, Temple GF, Kurman RJ, Jenson AB, Lancaster WD. Oncogenic association of specific human papillomavirus types with cervical neoplasia. J Natl Cancer Inst 1987;79.671-7.
18. Kurman RJ, Jenson AB, Lancaster WD. Papillomavirus infection of the cervix II. Relationship to intraepithelial neoplasia based on the presence of specific viral structural proteins. Am J Surg Pathol 1983;7:39-52.
19. Reid R, Cruin CP, Herschman BR, et al. Genital warts and cervical cancer. III. Subclinical papillomaviral infection and cervical neoplasia are linked by a spectrum of continuous morphologic and biologic change. Cancer 1984;53:943-53.
20. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991,265:472-7.
21. Schneider A. HPV infection in women and their male partners. Contemp Obstet Gynecol 1988;32(5).131-44
22. Grussendorf-Conen EI, de Villiers EM, Gissmann L. Human papillomavirus genomes in penile smears of healthy men. Lancet 1986;2:1092.
23. Crum CP, Ikenberg H, Richart RM, Gissmann L. Human papillomavirus type 16 and early cervical neoplasia. N Engl J Med 1984;310:880-3.
24. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection N Engl J Med 1992;327.1272-8.
25. Crum CP, Mitao M, Levine RU, Silverstein S. Cervical papillomaviruses segregate within morphologically distinct precancerous lesions. J Virol 1985;54:675-81.
26. Willett GD, Kurman RJ, Reid R, Greenberg M, Jenson AB, Lorincz AT. Correlation of the histologic appearance of intraepithelial neoplasia of the cervix with human papillomavirus types: emphasis on low grade lesions including so-called flat condyloma. Int J Gynecol Pathol 1989;8:18-25.
27. Howley PM. Role of the human papillomaviruses in human cancer. Cancer Res 1991;51:Suppl:5019s-5022s.
28. Werness BA, Levine AJ, Howley PM Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9
29. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
30. Münger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989; 63:4417-21
31. Scheffner M, Münger K, Byrne JC, Howley PM. The state of p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A 1991;88.5523-7.
32. Park DJ, Wilczynski SP, Paquette RL, Miller CW, Koeffler HP. p53 Mutations in HPV-negative cervical carcinoma. Oncogene 1994,9:205-10.
33. Johannesson G, Geirsson G, Day N. The effect of mass screening in Iceland, 1965-74, on the incidence and mortality of cervical carcinoma. Int J Cancer 1978;21.418-25.
34. Benedet JL, Anderson GH, Matisic JP. A comprehensive program for cervical cancer detection and management. Am J Obstet Gynecol 1992,166: 1254-9.
35. Devesa SS, Silverman DT, Young JL Jr, et al. Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst 1987,79 701-70
36. Koss LG. The Papanicolaou test for cervical cancer detection a triumph and a tragedy JAMA 1989;261:737-43
37. Worth AJ. The Walton report and its subsequent impact on cervical cancer screening programs in Canada. Obstet Gynecol 1984,63:135-9
38. Cook GA, Draper GJ. Trends in cervical cancer and carcinoma in situ in Great Britain Br J Cancer 1984;50:367-75.
39. Day NE. Effect of cervical cancer screening in Scandinavia. Obstet Gynecol 1984;63:714-8
40. van der Graaf Y, Vooijs GP, Gaillard HLJ, Go DMDS. Screening errors in cervical cytologic screening. Acta Cytol 1987,31 434-8.
41. Shingleton HM, Patrick RL, Johnston WW, Smith RA The current status of the Papanicolaou smear. CA Cancer J Clin 1995;45:305-20
42. Niloff J, Chamberlain J. Screening for cancer in women In: Sachs BP, Beard R, Papiernik E, Russell C, eds. Reproductive health care for women and babies Oxford, England: Oxford University Press, 1995 11-125
43. Update January 1992: the American Cancer Society guidelines for the cancer-related checkup. CA Cancer J Clin 1992;42:44-5.
44. National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. JAMA 1989;262 931-4
45. Kurman RJ, Malkasian GD Jr, Sedlis A, Solomon D. From Papanicolaou to Bethesda. the rationale for a new cervical cytologic classification. Obstet Gynecol 1991;77:779-82.
46. Sherman ME, Schiffman MH, Erozan YS, Wacholder S, Kurman RJ. The Bethesda System: a proposal for reporting abnormal cervical smears based on the reproducibility of cytopathologic diagnoses. Arch Pathol Lab Med 1992,116:1155-8.
47. Tabbara S, Saleh ADM, Andersen WA, Barber SR, Taylor PT, Crum CP. The Bethesda classification for squamous intraepithelial lesions: histologic, cytologic, and viral correlates. Obstet Gynecol 1992;79.338-46.
48. Herbst AL. The Bethesda system for cervical/vaginal cytologic diagnoses. Clin Obstet Gynecol 1992;35.22-7.
49. Idem Concerns regarding the Bethesda System. Int J Gynecol Pathol 1991;10:326-8.
50. Nasiell K, Roger V, Nasiell M Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol 1986;67:665-9.
51. Nasiell K, Nasiell M, Vaclavinkova V. Behavior of moderate cervical dysplasia during long-term follow-up. Obstet Gynecol 1983;61:609-14.
52. Hall JE, Walton L. Dysplasia of the cervix: a prospective study of 206 cases. Am J Obstet Gynecol 1968;100 662-71.
53. Beahrs OH, Henson DE, Hutter RVP, Myers MH, eds. Manual for staging of cancer. 3rd ed. Philadelphia: J.B. Lippincott, 1988.
54. Creasman WT. New gynecologic cancer staging. Gynecol Oncol 1995;58: 157-8.
55. Seski JC, Abell MR, Morley GW. Microinvasive squamous carcinoma of the cervix, definition, histologic analysis, late results of treatment. Obstet Gynecol 1977;50:410-4.
56. Kolstad P. Follow-up study of 232 patients with stage Ia1 and 411 patients with stage Ia2 squamous cell carcinoma of the cervix (microinvasive carcinoma). Gynecol Oncol 1989;33:265-72.
57. Nelson JH Jr, Averette HE, Richart RM. Detection, diagnostic evaluation and treatment of dysplasia and early carcinoma of the cervix. CA Cancer J Clin 1975;25:134-51.
58. Sedlis A, Sall S, Tsukada Y, et al. Microinvasive carcinoma of the uterine cervix: a clinical-pathologic study. Am J Obstet Gynecol 1979,133:64-74.
59. Newton M. Radical hysterectomy or radiotherapy for stage I cervical cancer: a prospective comparison with 5 and 10 years follow-up. Am J Obstet Gynecol 1975;123.535-42.
60. Allen HH, Collins JA Surgical management of carcinoma of the cervix. Am J Obstet Gynecol 1977;127:741-4.
61. Artman LE, Hoskins WJ, Bibro MC, et al. Radical hysterectomy and pelvic lymphadenectomy for stage IB carcinoma of the cervix: 21 years experience. Gynecol Oncol 1987,28.8-13
62. Hoskins WJ, Ford JH Jr, Lutz MH, Averette HE. Radical hysterectomy and pelvic lymphadenectomy for the management of early invasive cancer of the cervix Gynecol Oncol 1976,4:278-90.
63. Morley GW, Seski JC. Radical pelvic surgery versus radiation therapy for stage I carcinoma of the cervix (exclusive of microinvasion). Am J Obstet Gynecol 1976;126:785-98.
64. Hopkins MP, Morley GW. Radical hysterectomy versus radiation therapy for stage IB squamous cell cancer of the cervix. Cancer 1991,68:272-7.
65. Lerner HM, Jones HW III, Hill EC Radical surgery for the treatment of early invasive cervical carcinoma (stage IB): review of 15 years' experience Obstet Gynecol 1980;56:413-8.
66. Is pelvic radiation beneficial in postoperative management of stage Ib squamous cell carcinoma of the cervix with pelvic node metastasis treated by radical hysterectomy and pelvic lymphadenectomy? A report from the presidential panel at the 1979 Annual Meeting of the Society of Gynecologic Oncologists. Gynecol Oncol 1980;10:105-10.
67. Perez CA, Kurman RJ, Stehman FB, Thigpen JT Uterine cervix In Hoskins WJ, Perez CA, Young RC, eds Principles and practice of gynecologic oncology. Philadelphia: J.B. Lippincott, 1992:591-662.
68. Kinney WK, Alvarez RD, Reid GC, et al. Value of adjuvant whole-pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: a matched-control study Gynecol Oncol 1989;34:258-62.
69. Fuller AF Jr, Elliott N, Kosloff C, Lewis JL Jr. Lymph node metastases from carcinoma of the cervix, stage IB and IIA: implications for prognosis and treatment. Gynecol Oncol 1982;13.165-74.
70. Lovecchio JL, Averette HE, Donato D, Bell J 5-Year survival of patients with periaortic nodal metastases in clinical stage IB and IIA cervical carcinoma. Gynecol Oncol 1989;34:43-5.
71. Podczaski ES, Stryker JA, Kaminski P, et al. Extended-field radiation therapy for carcinoma of the cervix. Cancer 1990;66:251-8.
72. Potish R, Adcock L, Jones TK Jr, et al The morbidity and utility of periaortic radiotherapy in cervical carcinoma. Gynecol Oncol 1983;15:1-9.
73. Durrance FY. Radiotherapy following simple hysterectomy in patients with stage I and II carcinoma of the cervix. Am J Roentgenol Radium Ther Nucl Med 1968;102.165-9.
74. Nelson AJ III, Fletchcr GH, Wharton JT. Indications for adjunctive conservative extrafascial hysterectomy in selected cases of carcinoma of the uterine cervix. Am J Roentgenol Radium Ther Nucl Med 1975,123.91-9
75. Gallion HH, van Nagell JR, Donaldson ES, et al. Combined radiation therapy and extra-fascial hysterectomy in the treatment of stage IB barrel-shaped cervical cancer Cancer 1985;56:262-5
76. Fletcher GH. Cancer of the uterine cervix: Janeway lecture, 1970. Am J Roentgenol Radium Ther Nucl Med 1971;111 225-42.
77. Montana GS, Fowler WC, Varia MA, Walton LA, Mack Y, Shemanski L. Carcinoma of the cervix, stage III: results of radiation therapy. Cancer 1986;57:148-54.
78. Kramer C, Peschel RE, Goldberg N, et al Radiation treatment of FIGO stage IVA carcinoma of the cervix Gynecol Oncol 1989;32:323-6.
79. Morley GW, Hopkins MP, Lindenauer SM, Roberts JA. Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol 1989, 74:934-43
80. Rulledge FN, Smith JP, Wharton JT, O'Quinn AG. Pelvic exenteration: analysis of 296 patients. Am J Obstet Gynecol 1977;129:881-92.
81. Penalver MA, Bejany DE, Averette HE, Donato DM, Sevin BU, Suarez G. Continent urinary diversion in gynecologic oncology. Gynecol Oncol 1989;34:274-88.
82. Trelford JD, Goodnight J, Schneider P, Wolfe B, Sauder MT. Total exenteration, two or one ostomy Surg Gynecol Obstet 1992;175:126-8
83. Berck JS, Hacker NF, Lagasse LD. Vaginal reconstruction performed simultaneously with pelvic exenteration. Obstet Gyneeol 1984;63:318-23.
84. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix a Gynecologic Oncology Group study J Clin Oncol 1985;3. 1079-85.
85. Thigpen JT, Blessing JA, DiSaia PJ, Fowler WC Jr, Hatch KD A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989;32:198-202.
86. Omura GA Chemotherapy for cervix cancer. Semin Oncol 1994;21:54-62.
87. Sutton GP, Blessing JA, McGuire WP, Patton T, Look KY. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy. a Gynecologic Oncology Group study Am J Obstet Gynecol 1993;168: 805-7.
88. Stehman FB, Blessing JA, McGehee R, Barreit RJ A phase II evaluation of mitotactol in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 1989;7:1892-5.
89. Omura GA, Blessing J, Vaccarello L, et al A randomized trial of cisplatin versus cisplatin + mitolactol versus cisplatin + ifosfamide in advanced squamous carcinoma of the cervix (SCC) by the Gynecologic Oncology Group (GOG) Presented at the 27th Annual Meeting of the Society of Gynecologic Oncology, New Orleans, February 10-14, 1996. abstract .
90. Potter ME, Hatch KD, Potter MY, Shingleton HM, Baker VV Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer 1989;63:1283-6.
91. Hreshchyshyn MM, Aron BS, Boronow RC, Franklin EW III, Shingleton HM, Blessing JA. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys 1979;5:317-22.
92. Sardi J, Sananes C, Giaroli A, et al. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix Gynecol Oncol 1993;49:156-65
93. Souhami L, Gil RA, Allan SE, et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix J Clin Oncol 1991;9:970-7
94. Tattersall MHN, Lorvidhaya V, Vootiprux V, et al Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer J Clin Oncol 1995;13:444-51
95. Chauvergne J, Rohart J, Heron JF, et al. Randomized phase III trial of neoadjuvant chemotherapy (CT) + radiotherapy (RT) vs RT in stage IIB, III carcinoma of the cervix (CACX): a cooperative study of the French oncology centers. Proc Am Soc Clin Oncol 1988;7:136. abstract.
96. Kumar L, Kaushal R, Nandy M, et al. Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer. a randomized study. Gynecol Oncol 1994;54 307-15.
97. Lunt R. Worldwide early detection of cervical cancer. Obstet Gynecol 1984;63:708-13
98. Thigpen T, Vance RB, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix Semin Oncol 1995;22.Suppl 12:67-75
99. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al. 13-Cis-retinoic acid plus interferon α-2a: highly active systemic therapy for squamous cell carcinoma of the cervix J Natl Cancer Inst 1992;84:241-5.
100. Chen L, Mizuno MT, Singhal MC, et al. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992;148:2617-21.